PPW
BCRX icon

Pinnacle Private Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pinnacle Private Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$322K Buy
30,445
+400
+1% +$4.13K 0.13% 185
2022
Q1 		$489K Hold
30,045
– – 0.15% 155
2021
Q4 		$416K Buy
+30,045
New +$398K 0.13% 170

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pinnacle Private Wealth's BCRX Position: Q2 2022 in Review

Pinnacle Private Wealth increased its BioCryst Pharmaceuticals (BCRX) stake by 1.3% in Q2 2022, buying an estimated $4.13K and bringing the position to 30,445 shares worth $322K. The position accounts for 0.13% of the portfolio, ranked #185.

Pinnacle Private Wealth first reported a position in BCRX in Q4 2021 and has held it in 3 quarters since. The position peaked at $489K in Q1 2022. 220 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Pinnacle Private Wealth held 30,445 shares of BioCryst Pharmaceuticals worth $322K as of Q2 2022.
  • Pinnacle Private Wealth bought 400 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $4.13K.
  • BioCryst Pharmaceuticals made up 0.13% of Pinnacle Private Wealth's portfolio in Q2 2022, its #185 holding.
  • Pinnacle Private Wealth first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
  • Pinnacle Private Wealth's BioCryst Pharmaceuticals position peaked at $489K in Q1 2022.
  • 220 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Pinnacle Private Wealth's 13F filing for Q2 2022, filed 15 Jul 2022.